FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509792196> ?p ?o ?g. }

• W2509792196 endingPage "5491" @default.
• W2509792196 startingPage "5483" @default.
• W2509792196 abstract "Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifungal agent used for the treatment of invasive fungal infections. The objective of this analysis was to develop a population pharmacokinetic (PPK) model to identify covariates that affect isavuconazole pharmacokinetics and to determine the probability of target attainment (PTA) for invasive aspergillosis patients. Data from nine phase 1 studies and one phase 3 clinical trial (SECURE) were pooled to develop the PPK model (NONMEM, version 7.2). Stepwise covariate modeling was performed in Perl-speaks-NONMEM, version 3.7.6. The area under the curve (AUC) at steady state was calculated for 5,000 patients by using Monte Carlo simulations. The PTA using the estimated pharmacodynamic (PD) target value (total AUC/MIC ratio) estimated from in vivo PD studies of invasive aspergillosis over a range of MIC values was calculated using simulated patient AUC values. A two-compartment model with a Weibull absorption function and a first-order elimination process adequately described plasma isavuconazole concentrations. The mean estimate for isavuconazole clearance was 2.360 liters/h (percent coefficient of variation [%CV], 34%), and the mean AUC from 0 to 24 h (AUC0-24) was ∼100 mg·h/liter. Clearance was approximately 36% lower in Asians than in Caucasians. The PTA calculated over a range of MIC values by use of the nonneutropenic murine efficacy index corresponding to 90% survival indicated that adequate isavuconazole exposures were achieved in >90% of simulated patients to treat infections with MICs up to and including 1 mg/liter according to European Committee on Antimicrobial Susceptibility Testing methodology and in >90% of simulated patients for infections with MICs up to and including 0.5 mg/liter according to Clinical and Laboratory Standards Institute methodology. The highest MIC result for PTA was the same for Caucasian and Asian patients." @default.
• W2509792196 created "2016-09-16" @default.
• W2509792196 creator A5006107745 @default.
• W2509792196 creator A5014325226 @default.
• W2509792196 creator A5015217929 @default.
• W2509792196 creator A5029494840 @default.
• W2509792196 creator A5046323853 @default.
• W2509792196 creator A5062349191 @default.
• W2509792196 date "2016-09-01" @default.
• W2509792196 modified "2023-10-16" @default.
• W2509792196 title "Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi" @default.
• W2509792196 cites W152085397 @default.
• W2509792196 cites W1546727052 @default.
• W2509792196 cites W1924733673 @default.
• W2509792196 cites W1976764897 @default.
• W2509792196 cites W1982143055 @default.
• W2509792196 cites W1986071890 @default.
• W2509792196 cites W2030747862 @default.
• W2509792196 cites W2053425195 @default.
• W2509792196 cites W2058571383 @default.
• W2509792196 cites W2067050070 @default.
• W2509792196 cites W2073263704 @default.
• W2509792196 cites W2074444669 @default.
• W2509792196 cites W2096521991 @default.
• W2509792196 cites W2102596464 @default.
• W2509792196 cites W2107719786 @default.
• W2509792196 cites W2123134253 @default.
• W2509792196 cites W2132035840 @default.
• W2509792196 cites W2134546466 @default.
• W2509792196 cites W2134631351 @default.
• W2509792196 cites W2139467279 @default.
• W2509792196 cites W2142715639 @default.
• W2509792196 cites W2145484866 @default.
• W2509792196 cites W2154336328 @default.
• W2509792196 cites W2157308892 @default.
• W2509792196 cites W2157983082 @default.
• W2509792196 cites W2158568849 @default.
• W2509792196 cites W2178821151 @default.
• W2509792196 cites W2189861011 @default.
• W2509792196 cites W2290207163 @default.
• W2509792196 cites W2338427714 @default.
• W2509792196 cites W627913863 @default.
• W2509792196 doi "https://doi.org/10.1128/aac.02819-15" @default.
• W2509792196 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4997882" @default.
• W2509792196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27381396" @default.
• W2509792196 hasPublicationYear "2016" @default.
• W2509792196 type Work @default.
• W2509792196 sameAs 2509792196 @default.
• W2509792196 citedByCount "89" @default.
• W2509792196 countsByYear W25097921962016 @default.
• W2509792196 countsByYear W25097921962017 @default.
• W2509792196 countsByYear W25097921962018 @default.
• W2509792196 countsByYear W25097921962019 @default.
• W2509792196 countsByYear W25097921962020 @default.
• W2509792196 countsByYear W25097921962021 @default.
• W2509792196 countsByYear W25097921962022 @default.
• W2509792196 countsByYear W25097921962023 @default.
• W2509792196 crossrefType "journal-article" @default.
• W2509792196 hasAuthorship W2509792196A5006107745 @default.
• W2509792196 hasAuthorship W2509792196A5014325226 @default.
• W2509792196 hasAuthorship W2509792196A5015217929 @default.
• W2509792196 hasAuthorship W2509792196A5029494840 @default.
• W2509792196 hasAuthorship W2509792196A5046323853 @default.
• W2509792196 hasAuthorship W2509792196A5062349191 @default.
• W2509792196 hasBestOaLocation W25097921961 @default.
• W2509792196 hasConcept C111113717 @default.
• W2509792196 hasConcept C112705442 @default.
• W2509792196 hasConcept C126322002 @default.
• W2509792196 hasConcept C203014093 @default.
• W2509792196 hasConcept C2776239304 @default.
• W2509792196 hasConcept C2776391196 @default.
• W2509792196 hasConcept C2777071850 @default.
• W2509792196 hasConcept C2779548794 @default.
• W2509792196 hasConcept C2908647359 @default.
• W2509792196 hasConcept C71924100 @default.
• W2509792196 hasConcept C76318530 @default.
• W2509792196 hasConcept C86803240 @default.
• W2509792196 hasConcept C89423630 @default.
• W2509792196 hasConcept C98274493 @default.
• W2509792196 hasConcept C99454951 @default.
• W2509792196 hasConceptScore W2509792196C111113717 @default.
• W2509792196 hasConceptScore W2509792196C112705442 @default.
• W2509792196 hasConceptScore W2509792196C126322002 @default.
• W2509792196 hasConceptScore W2509792196C203014093 @default.
• W2509792196 hasConceptScore W2509792196C2776239304 @default.
• W2509792196 hasConceptScore W2509792196C2776391196 @default.
• W2509792196 hasConceptScore W2509792196C2777071850 @default.
• W2509792196 hasConceptScore W2509792196C2779548794 @default.
• W2509792196 hasConceptScore W2509792196C2908647359 @default.
• W2509792196 hasConceptScore W2509792196C71924100 @default.
• W2509792196 hasConceptScore W2509792196C76318530 @default.
• W2509792196 hasConceptScore W2509792196C86803240 @default.
• W2509792196 hasConceptScore W2509792196C89423630 @default.
• W2509792196 hasConceptScore W2509792196C98274493 @default.
• W2509792196 hasConceptScore W2509792196C99454951 @default.
• W2509792196 hasFunder F4320332563 @default.
• W2509792196 hasIssue "9" @default.
• W2509792196 hasLocation W25097921961 @default.

• next